logo-loader
viewOpen Orphan PLC

Jefferies 2019 London Healthcare Conference

/**/ sup{font-size:80%}link{ color: blue }visited{ color: #954F72 } .y{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.y{}p.ak{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm}span.al{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}p.am{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align: center}span.an{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.ao{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align: center}span.ap{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.h,li.h,div.h{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}p.aq{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify} span.ar{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}span.as{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.r,li.r,div.r{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}span.at{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.au{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.t,li.t,div.t{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}span.ac{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.k{}span.av{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.ae{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black} span.q{}span.ad{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}span.aa{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}p.aw{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}span.ai{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}p.ax{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";} /**/
RNS Number : 4938T
Open Orphan PLC
15 November 2019
 

15th November 2019

Open Orphan Plc

("Open Orphan" or the "Company")

                              Open Orphan to attend Jefferies 2019 London Healthcare Conference

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending the Jefferies 2019 London Healthcare Conference on 20th-21st November 2019 in London, UK.

The conference will be attended by a range of international healthcare executives and institutional investors who will gather to address near and long-term investment opportunities and to discuss the mechanisms driving global healthcare.

Open Orphan's Chief Executive Officer, Cathal Friel, will be in attendance and will be doing one-on-one meetings with attendees at the conference.

Enquiries:

Open Orphan Plc Tel: +353 (0)1 6440007
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services businesses. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAGGGRPGUPBGMC

Quick facts: Open Orphan PLC

Price: 5.15

Market: AIM
Market Cap: £13.11 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: DeepMatter to collaborate with AstraZeneca

Headlines from the Proactive UK newsroom. DeepMatter (LON:DMTR) has agreed a tie-up with AstraZeneca to combine their drug development technology platforms. Deepmatter uses AI to monitor and record chemical reactions during drug development. Rare disease database group Open Orphan...

12 hours, 25 minutes ago